Saturday 31 October 2026
Export LLY’s income statement to Excel — free account
Eli Lilly and Company
LLY Healthcare Drug Manufacturers General
Eli Lilly and Company’s revenue for fiscal 2025 (year ended December 2025) was $65.2 billion, up 44.7% from fiscal 2024. In the quarter to June 2026, revenue grew 47.7%, EPS grew 26.2%, free cash flow grew 458.1% and total debt rose 37.6%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for twenty-five consecutive years, revenue growth for five.
1,415.16
41.46
+3.02%
Follow LLY
Alert me
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
46.83 | 65.93 | 102.10 | 52.90 | 44.99 | 24.83 | 14.97 | 36.97 | 0.00 | 28.91 |
Piotroski F-Score |
7 | 6 | 5 | 7 | 6 | 6 | 6 | 9 | 4 | 6 |
Altman Z-Score |
8.61 | 7.89 | 6.99 | 6.47 | 5.14 | 3.57 | 3.23 | 3.52 | 2.75 | 3.42 |
P/S ratio |
14.79 | 15.44 | 15.62 | 11.53 | 8.85 | 6.24 | 5.48 | 5.53 | 4.46 | 3.72 |
P/FCF ratio |
86.31 | 116.64 | 216.52 | 56.77 | 38.74 | 27.75 | 29.05 | 25.18 | 18.00 | 18.37 |
Altman Z″-Score (non-manufacturers) |
3.79 | 2.26 | 1.26 | 2.04 | 2.17 | 2.27 | 1.66 | 3.03 | 2.35 | 3.21 |
Beneish M-Score |
(1.91) | (2.21) | (2.18) | (2.58) | (2.47) | (2.26) | (2.52) | (2.64) | (3.04) | (2.62) |
P/Operating CF |
299.05 | 281.04 | (1,708.65) | 197.95 | 110.77 | 84.42 | 62.32 | 82.09 | 51.10 | 39.35 |
Dividend Safety Score |
86 | — | — | — | — | — | — | — | — | — |
P/B ratio |
36.34 | 48.72 | 49.07 | 30.54 | 27.37 | 26.31 | 45.34 | 10.90 | 7.64 | 5.61 |
Price to Tangible BV |
68.31 | 297.63 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 14.03 | 27.25 | 13.73 |
EV/Sales |
15.34 | 16.02 | 16.14 | 12.02 | 9.30 | 6.77 | 6.07 | 5.62 | 4.56 | 3.83 |
EV/EBITDA |
35.32 | 49.20 | 68.98 | 39.67 | 33.33 | 22.51 | 21.81 | 23.47 | 25.49 | 17.09 |
EV/Operating CF |
59.45 | 81.84 | 129.89 | 45.24 | 35.77 | 25.56 | 27.99 | 21.85 | 16.21 | 16.76 |
EV/FCF |
89.46 | 121.06 | 223.69 | 59.19 | 40.75 | 30.09 | 32.13 | 25.56 | 18.39 | 18.92 |
Quick Ratio |
0.78 | 0.58 | 0.52 | 0.63 | 0.80 | 0.85 | 0.68 | 1.11 | 0.91 | 0.98 |
Current Ratio |
1.58 | 1.15 | 0.94 | 1.05 | 1.23 | 1.40 | 1.16 | 1.73 | 1.32 | 1.37 |
Net Debt/EBITDA |
1.19 | 1.72 | 1.93 | 1.45 | 1.45 | 1.75 | 2.09 | 0.56 | 1.57 | 0.90 |
Debt/Assets |
36.33% | 36.24% | 28.62% | 29.78% | 31.44% | 35.59% | 39.30% | 23.45% | 30.34% | 26.55% |
Debt/Equity |
1.54 | 2.00 | 1.69 | 1.37 | 1.68 | 2.85 | 5.72 | 0.94 | 1.17 | 0.73 |
Asset Turnover |
0.68 | 0.63 | 0.60 | 0.58 | 0.59 | 0.57 | 0.54 | 0.48 | 0.48 | 0.57 |
Operating CF/Net income |
0.81 | 0.83 | 0.81 | 1.21 | 1.32 | 1.05 | 0.58 | 1.71 | (27.51) | 1.77 |
Capex/Depreciation |
(3.93) | (2.86) | (2.26) | (1.22) | (0.85) | (1.05) | (0.84) | (0.75) | (0.69) | (0.64) |
| 101.16% | 84.26% | 48.43% | 62.67% | 74.52% | 145.32% | 122.26% | 28.63% | (1.59%) | 19.10% | |
| 21.59% | 14.84% | 9.23% | 12.71% | 11.70% | 14.42% | 20.00% | 7.27% | (0.49%) | 7.36% | |
ROIC |
27.34% | 20.39% | 15.37% | 19.12% | 19.29% | 20.20% | 19.80% | 16.01% | 7.25% | 11.11% |
Return on Tangible Assets |
45.79% | 49.33% | 46.18% | 56.56% | 45.07% | 45.33% | 84.82% | 19.40% | (1.51%) | 22.14% |
Average Days of Receivables |
112.87 | 107.58 | 121.26 | 109.46 | 104.75 | 103.06 | 90.62 | 98.10 | 96.16 | 81.98 |
Research and Development Expense of Revenue |
20.46% | 24.40% | 27.29% | 25.19% | 24.47% | 24.35% | 25.07% | 23.50% | 25.51% | 25.02% |
Selling, General and Administrative Expense of Revenue |
17.02% | 19.08% | 21.70% | 22.57% | 22.71% | 24.94% | 27.84% | 27.80% | 29.95% | 30.76% |
Intangible Assets out of Total Assets |
0.11 | 0.15 | 0.19 | 0.23 | 0.24 | 0.24 | 0.26 | 0.06 | 0.19 | 0.21 |
Share Based Compensation of Revenue |
0.96% | 1.43% | 1.84% | 1.30% | 1.21% | 1.26% | 1.40% | 1.30% | 1.41% | 1.20% |
Graham Net Nets |
(0.03) | (0.05) | (0.05) | (0.06) | (0.08) | (0.15) | (0.19) | (0.10) | (0.16) | (0.12) |
Graham Number |
123.57 | 64.62 | 39.68 | 43.07 | 37.34 | 31.34 | 23.93 | 27.34 | 0.00 | 27.79 |
Earnings Yield |
2.14% | 1.52% | 0.98% | 1.89% | 2.22% | 4.03% | 6.68% | 2.70% | (0.24%) | 3.46% |
Free Cash Flow Yield |
1.16% | 0.86% | 0.46% | 1.76% | 2.58% | 3.60% | 3.44% | 3.97% | 5.56% | 5.44% |
Revenue per Share |
72.64 | 50.01 | 37.91 | 31.65 | 31.22 | 27.04 | 23.97 | 20.91 | 18.99 | 20.05 |
Operating CF per Share |
18.74 | 9.79 | 4.71 | 8.41 | 8.12 | 7.16 | 5.19 | 5.38 | 5.34 | 4.58 |
Capex per Share |
(8.74) | (5.62) | (3.83) | (2.06) | (1.44) | (1.53) | (1.11) | (1.18) | (1.02) | (0.91) |
Free Cash Flow per Share |
10.00 | 4.18 | 0.88 | 6.36 | 6.68 | 5.63 | 4.08 | 4.20 | 4.31 | 3.67 |
Cash per Share |
8.10 | 3.63 | 3.25 | 2.45 | 4.31 | 4.06 | 2.62 | 7.21 | 7.64 | 5.71 |
Shareholders Equity per Share |
29.57 | 15.85 | 12.07 | 11.95 | 10.09 | 6.42 | 2.90 | 10.61 | 11.09 | 13.30 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
29.57 | 15.85 | 12.07 | 11.95 | 10.09 | 6.42 | 2.90 | 10.61 | 11.09 | 13.30 |
Free Cash Flow |
8,972.00 | 3,760.00 | 792.00 | 5,731.40 | 6,056.10 | 5,111.70 | 3,802.70 | 4,313.90 | 4,538.80 | 3,887.40 |
Working Capital |
20,401.00 | 4,364.00 | (1,566.20) | 896.30 | 3,399.70 | 4,980.50 | 1,934.40 | 8,661.50 | 4,666.20 | 4,114.80 |
Capital Expenditures |
(7,841.00) | (5,058.00) | (3,448.00) | (1,854.30) | (1,309.80) | (1,387.90) | (1,033.90) | (1,210.60) | (1,076.80) | (963.60) |
Net Current Asset Value |
(30,312.00) | (31,703.00) | (27,415.60) | (20,679.90) | (21,198.80) | (23,345.80) | (22,877.40) | (12,449.70) | (14,111.00) | (9,624.00) |
EV/EBIT |
38.00 | 55.95 | 85.29 | 48.15 | 41.45 | 27.43 | 27.21 | 34.16 | 45.43 | 24.93 |
Capex to Sales |
0.12 | 0.11 | 0.10 | 0.07 | 0.05 | 0.06 | 0.05 | 0.06 | 0.05 | 0.05 |
Price to Operating Income |
36.66 | 53.90 | 82.56 | 46.18 | 39.41 | 25.30 | 24.60 | 33.65 | 44.47 | 24.21 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.08 | 0.10 | 0.12 | 0.15 | 0.17 | 0.15 | 0.16 | 0.20 | 0.18 | 0.18 |
Cash ROIC |
12.02% | 8.16% | 2.47% | 20.67% | 21.32% | 19.58% | 18.48% | 15.07% | 13.61% | 12.78% |
Accounts Receivable Turnover |
3.90 | 3.66 | 3.43 | 3.42 | 3.76 | 3.94 | 3.94 | 3.89 | 3.98 | 4.80 |
Accounts Payable Turnover |
2.57 | 2.89 | 3.13 | 3.68 | 4.46 | 3.64 | 3.61 | 3.58 | 3.22 | 4.25 |
Inventory Turnover |
1.04 | 1.26 | 1.40 | 1.62 | 1.86 | 1.53 | 1.50 | 1.24 | 1.11 | 1.63 |
Average Days of Payables |
177.65 | 140.01 | 133.94 | 106.29 | 83.38 | 106.95 | 108.64 | 94.11 | 115.77 | 86.25 |
Days of Inventory on Hand |
453.91 | 329.06 | 297.53 | 237.27 | 193.96 | 264.95 | 246.68 | 241.54 | 365.87 | 227.68 |
Average Receivables |
16,715.50 | 12,306.10 | 9,947.55 | 8,343.05 | 7,528.10 | 6,235.25 | 5,659.15 | 5,519.50 | 5,014.25 | 4,418.95 |
Average Payables |
4,304.00 | 2,913.90 | 2,264.70 | 1,800.60 | 1,638.65 | 1,506.00 | 1,306.20 | 1,308.90 | 1,380.00 | 1,343.75 |
Average Inventory |
10,666.50 | 6,680.90 | 5,041.25 | 4,097.85 | 3,933.15 | 3,585.50 | 3,144.40 | 3,778.20 | 4,010.10 | 3,503.85 |
Average Assets |
95,595.50 | 71,360.65 | 56,748.05 | 49,147.90 | 47,719.55 | 42,959.60 | 41,597.25 | 44,444.70 | 41,893.45 | 37,187.40 |
Average Common Equity |
20,403.50 | 12,567.85 | 10,819.55 | 9,965.10 | 7,490.00 | 4,262.15 | 6,804.10 | 11,288.50 | 12,874.20 | 14,335.40 |
Columns are period end dates